 The FDA has accepted for review Amicus Therapeutics Incs NASDAQ: FOLD Biologics License Application BLA for cipaglucosidase alfa and the New Drug Application NDA for miglustat for AT-GAA. Also Read: Amicuss Fabry Disease Medicine Gets European Approval For Use In Adolescents 